|March 12, 2019|
|Verastem Oncology to Present at Upcoming Investor Conferences|
BOSTON--(BUSINESS WIRE)--Mar. 12, 2019--
Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused
on developing and commercializing medicines seeking to improve the
survival and quality of life of cancer patients, today announced that
the Company will present at the following upcoming investor conferences:
The 31st Annual ROTH Conference on Tuesday, March 19, 2019
at 12:00pm PDT in Dana Point, CA, USA
The Oppenheimer 29th Annual Healthcare Conference on
Tuesday, March 19, 2019 at 11:30am EDT in New York City, NY, USA
A live webcast of these presentations will be available on the investors
section of the Company’s website at www.verastem.com.
An archived presentation will be available for 90 days.
About Verastem Oncology
Verastem Oncology (Nasdaq:VSTM) is a commercial biopharmaceutical
company committed to the development and commercialization of medicines
to improve the lives of patients diagnosed with cancer. We are driven by
the strength, tenacity and courage of those battling cancer –
single-minded in our resolve to deliver new therapies that not only keep
cancer at bay, but improve the lives of patients diagnosed with cancer.
Because for us, it’s personal.
Our first FDA approved product is now available for the treatment of
patients with certain types of indolent non-Hodgkin’s lymphoma (iNHL).
Our pipeline comprises product candidates that seek to treat cancer by
modulating the local tumor microenvironment. For more information,
please visit www.verastem.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190312005120/en/
Source: Verastem, Inc.
Senior Director, Investor
Relations and Corporate Communications